SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla jumps on getting final approval for Arformoterol Tartrate Inhalation Solution

23 Jun 2021 Evaluate

Cipla is currently trading at Rs. 961.35, up by 5.70 points or 0.60% from its previous closing of Rs. 955.65 on the BSE.

The scrip opened at Rs. 955.65 and has touched a high and low of Rs. 965.80 and Rs. 955.65 respectively. So far 616965 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 982.05 on 11-Jun-2021 and a 52 week low of Rs. 621.50 on 01-Jul-2020.

Last one week high and low of the scrip stood at Rs. 967.45 and Rs. 943.50 respectively. The current market cap of the company is Rs. 77655.10 crore.

The promoters holding in the company stood at 36.73%, while Institutions and Non-Institutions held 40.43% and 22.84% respectively.

Cipla has received final approval for its Abbreviated New Drug Application (ANDA) for Arformoterol Tartrate Inhalation Solution 15 mcg / 2 mL from the United States Food and Drug Administration (US FDA). Cipla’s Arformoterol Tartrate Inhalation Solution 15 mcg / 2 mL is AN-rated generic therapeutic equivalent version of Sunovion Pharmaceuticals Inc.’s Brovana.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla Share Price

1233.30 0.40 (0.03%)
22-Apr-2026 11:49 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1659.55
Dr. Reddys Lab 1219.60
Cipla 1233.30
Zydus Lifesciences 930.25
Lupin 2308.05
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×